

Record ID	TGR at baseline	TGR at PD	(TGR at PD) – (TGR at baseline)
20	0	0	0
34	0	0	0
118	12.388174267142	1.7414546411449683	-10.646719625997
131	12.224674712953787	0	-12.224674712953787
100	159.09177649222505	0	-159.09177649222505
14	20.64531550717712	0	-20.64531550717712
123	24.339482530031532	2.3903980877528763	-21.949084442278654
82	45.495517688939536	22.62471283020291	-22.870804858736626
99	263.9109874292884	-13.598883758907165	-277.5098711881956
143	50.141727065929366	17.897769952690457	-32.243957113238906
139	77.40422359922444	44.235411086081825	-33.16881251314261
96	38.83106847625	0	-38.83106847625
85	53.82943084646092	0	-53.82943084646092
125	543.5177915994036	0	-543.5177915994036
113	3.9356266368534	4.3653138036101	0.42968716675673
51	10.67980381222795	20.852463043851486	10.172659231623536
32	-9.149241654065154	4.358268100050711	13.507509754115866
65	0	20.13360462037759	20.13360462037759
138	11.730493284870281	15.951503891896234	4.221010607025953
130	0	NA	NA
61	NA	20.31635783321264	NA
107	NA	0	NA
135	NA	NA	NA
16	10.93009117412	NA	NA
95	NA	NA	NA
25	NA	27.26758888817349	NA
78	NA	13.979438856195	NA
38	NA	-7.0184637492031	NA
59	NA	0	NA
137	NA	NA	NA
89	NA	NA	NA
92	NA	8.031584359335241	NA
115	NA	0	NA
116	NA	-35.12330378991061	NA
56	36.593193844281	NA	NA
136	NA	NA	NA
142	NA	91.11066136359516	NA
128	4.174579567361	NA	NA
127	5.121696112977525	NA	NA
67	NA	NA	NA
122	NA	45.91109068426906	NA
129	NA	NA	NA
63	NA	NA	NA
			(PD – baseline ≤ 0) OR (PD ≤ 0): n= 19

Supplementary Table S1: Patients with potential benefit of continuing PD-1/PD-L1 blockade beyond PD. Highlighted lines are patients whose TGR assessed at PD was either null/negative, or inferior to TGR measured at baseline before ICI when both time points were available. Total = 19/43 patients.

Oligo PD lesions	New lesions at PD2	Interval PD-PD2 (months)	TGR oligo (%/month)
1	No	2,73	0,00
1	No	2,79	2,93
2	No	3,35	4,80
2	No	2,30	7,33
1	No	1,28	11,53
1	No	3,48	12,12
2	No	2,60	18,93
1	No	3,88	20,07
2	No	1,28	20,32
2	No	2,30	20,85
1	No	1,54	22,24
1	No	3,88	23,00
1	No	1,12	26,12
1	No	2,00	31,16
1	No	1,15	32,12
1	No	2,07	32,71
2	No	2,33	34,20
2	No	2,76	35,04
1	No	2,07	35,15
1	No	1,91	41,68
1	No	3,61	54,62
1	No	2,33	58,30
2	No	1,77	145,31
2	No	2,23	160,37
1	Yes	2,33	NA
2	Yes	2,99	NA
1	Yes	2,46	NA
1	Yes	2,04	NA
3	NA	NA	NA
3	NA	NA	NA
1	NA	NA	NA
2	NA	NA	NA
		Mean PD-PD2	Median TGR oligo
		2,378165869	24,56 (IQR 17,84)

Supplementary Table S2: Oligoprogression characterization. « Oligo PD lesions » : number of progressing lesions in OPD under PD-1/PD-L1 blockade ; « New lesions PD2 » : presence of new lesions on « PD2 » imagery following first PD ; « Interval PD-PD2 » : time (months) elapsed between both imageries ; « TGR oligo » : TGR calculated specifically on progressing lesions in assessable OPD patient.

		Primary resistance (N=105)	PD after DCB (N=43)
No treatment		38	6
Subsequent treatment	Anti-PD-1/PD-L1 monotherapy continuation + locoregional treatment	2	3
	Anti-PD-1/PD-L1 monotherapy rechallenge after toxicity	0	3
	Anti-PD-1/PD-L1 monotherapy continuation despite PD	9	5
	Locoregional treatment alone	1	2
	New systemic therapy	55	24
	Platine doublet +or- bevacizumab	11	3
	Taxane +or- bevacizumab	25	6
	Tyrosine kinase inhibitor	8	3
	Pemetrexed	5	7
	Vinorelbine	3	0
	Gemcitabine	3	5

Supplementary Table S3: Subsequent treatment after primary resistance or PD after DCB with anti-PD-1/PD-L1.
« Locoregional treatment » : radiation therapy, local ablative therapies or surgery